Immunovia announces updated financial calendar
LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, updates its financial calendar for 2024.
| Annual Report to be published | April 29, 2024 |
| Q1 Report, 2024 | April 29, 2024 |
| Annual General Meeting | June 4, 2024 |
| Q2 Report, 2024 | August 22, 2024 |
| Q3 Report, 2024 | November 14, 2024 |
For more information, please contact:
Karin Almqvist Liwendahl
Chief Financial Officer
+46 709 11 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
USA is the world’s largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com